HK Stock Market Move | PEGBIO CO-B(02565) rose by over 21%, partnering with Rani to advance multiple innovative metabolic assets for oral administration.

PEGBIO CO-B(02565) surged more than 21%, rising 21.88% to HK$6.77 as of the time of this report, with a trading volume of HK$60.869 million. In terms of news, Pegbio Bio announced this morning that it has recently signed a memorandum of understanding with the United States-listed company Rani Therapeutics (RANI.US) on the Nasdaq. The two parties plan to use Rani's proprietary RaniPill platform to conduct oral delivery and pre-clinical development of several innovative candidate assets in Pegbio's pipeline for obesity and metabolic diseases, and explore the research, production, and commercialization cooperation of related products in markets outside of China. According to information disclosed by Rani, the two parties plan to select suitable candidate projects for oral delivery from Pegbio's multiple metabolic innovative assets and aim to drive the most promising projects into clinical development. It is worth mentioning that Pegbio has already formed a gradient pipeline composed of commercialized products Vepinapeptide, long-acting platform CR059, and next-generation obesity candidate assets represented by APGP6. The addition of RaniPill may introduce a new variable for metabolic assets at different stages and mechanisms: oral administration. This means that Pegbio's valuation logic may extend from one commercialized product to the next-generation pipeline, dosage form innovation, and global BD in three dimensions.